The Motley Fool

Fisher & Paykel Healthcare share price on watch after guidance upgrade

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price will be on watch today after it provided an update on its guidance for FY 2019.

What did Fisher & Paykel Healthcare announce?

This month there have been countless companies including Cochlear Limited (ASX: COH) and Flight Centre Travel Group Ltd (ASX: FLT) warning about the negative impacts the coronavirus outbreak is having on their businesses.

But one company that has experienced a surge in demand following the devastating outbreak of this virus is Fisher & Paykel Healthcare.

This morning it revealed that it has experienced better-than-expected sales in its Hospital product business following an increase in demand from China following the coronavirus outbreak.

Combined with higher than expected Homecare sales, this has led to the company upgrading its revenue and earnings guidance for the full year.

Guidance upgrade.

Management previously expected operating revenue to be approximately NZ$1.19 billion and net profit after tax to be approximately NZ$255 million to NZ$265 million for the 12 months ending March 31.

But this has now been lifted to revenue of approximately NZ$1.2 billion and net profit after tax in the range of approximately NZ$260 million to NZ$270 million.

Fisher & Paykel Healthcare’s Managing Director and CEO, Lewis Gradon, explained: “We’ve seen better-than-expected sales in our Homecare product group combined with continued strong growth in our Hospital product group. This includes an increase in demand from China related to the COVID-19 coronavirus outbreak.”

In addition to this, Mr Gradon advised that the company’s supply chain should not be impacted greatly by the coronavirus as it does not have a manufacturing facility in China. And while some of its suppliers of raw materials are based in China, it doesn’t expect any meaningful disruption.

Mr Gradon said: “At this stage, we do not anticipate any significant impact on supply to our existing customers. We will continue to assess this on an ongoing basis, particularly if the outbreak escalates or continues for a prolonged period.”

These 3 stocks could be the next big movers in 2020

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

*Returns as of 6/8/2020

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia owns shares of and has recommended Flight Centre Travel Group Limited. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Related Articles...